Therapeutic uses of gene edited fibroblasts
AssigneeFigene, LLC
InventorsPete O'HEERON, Thomas ICHIM
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods and compositions of engineered fibroblast cells with one or more types of modifications such that the cell has a reduced immune response either alone, in association with other immune cells, or both. In some embodiments, one or more targets are modified on the surface of the cell. In specific embodiments, engineered cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity.
Claims32
An engineered fibroblast cell comprising a reduction in the expression of a polynucleotide sequence encoding an immunogenic component selected from the group consisting of:
- a) a human leukocyte antigen (HLA);
- b) a costimulatory molecule;
- c) an adhesion molecule;
- d) a polypeptide associated with an increase in the expression of human leukocyte antigens;
- e) a polypeptide associated with fibrosis;
- and
- f) a combination thereof.
Dependencies are inferred from the claim text.